🔗 Share this article

Given that the US continues making unprecedented revisions to its vaccine guidelines, an unexpected name has surfaced unexpectedly: Tracy Beth Høeg, a Danish American physician and public health researcher who first made her name by expressing skepticism about COVID-19 vaccinations throughout the global health crisis and has concentrated on alleged deaths after COVID-19 immunization in her recent time at the FDA.

Planned Shifts to Childhood Vaccine Program

Health officials had intended to announce major changes to the pediatric immunization program earlier this month, aligning the US with the Danish immunization schedule, sources say – a substantial departure that would place the US out of step with a large portion of the world with insufficient data for improved outcomes. The planned update has been pushed back until the next year.

Instead of Vinay Prasad, Høeg is listed to address the audience at the meeting. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the office this year.

A Shift at the Regulatory Body

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Prasad solidify control at the FDA – and it signals a greater focus upon dismantling previously authorized vaccines at the FDA.

Høeg has frequently advocated for halting certain pediatric vaccine recommendations in the US so as to align more similar to Denmark, a country with universal health coverage and a population roughly the size of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on vaccines – traditionally the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Concerns Over Expertise

Dr. Høeg has little discernible experience in pharmaceutical research, regulation or management, which has been standard for past heads of the CBER. She has worked at the FDA as a key advisor to the FDA chief and CBER since spring.

“She appears not to have any of the qualifications” for overseeing the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a clinical trial. She has no expertise in managing a large organization. She is not an expert in industry regulation.”

Previous directors of CBER would “grasp laws and regulations and the research of medication creation”, noted a former acting FDA commissioner. “Objectively, she doesn’t have the sort of resume that previous people who headed the center have had.”

This division has an enormous range of responsibilities at the agency, she emphasized.

“Everybody just focuses on the innovative therapies, but the generic program approves a multitude of off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and more, and all of those need to be supervised,” she noted. “The area you overlook, that is the part that I always told people is going to come back to haunt you.”

There is also, a substantial administrative element to the job, which supervises more than 5,000 personnel. “It’s a enormous management job, if you execute it properly,” Woodcock added.

Response and Controversial Initiatives

When asked about questions about Høeg’s qualifications and whether this appointment signifies increased cooperation among agency officials on immunizations, a press secretary stated that the “questions rely on flawed assumptions”.

“This background aligns with the responsibilities of her position,” the official explained, citing the months Høeg spent counseling the FDA commissioner on “pharmaceutical safety and approval science, including computational safety modeling and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the agency head's recently launched expedited review system, a controversial rapid therapy clearance system that allegedly worried her preceding directors. “How are these medications being chosen for this fast-track system? Who is making the decisions?” Howard asked. “There’s a lot of lack of transparency going on at the regulatory body right now.”

In general, he stated, “the agency appears to be shifting towards less stringent rules of pharmaceuticals, aside from immunizations.”

Documented Track Record on Vaccines

Concerning vaccines, Høeg has a more established, if concerning, past, critics have noted. She released a study using unverified volunteer-provided data to determine the incidence of myocarditis following COVID-19 vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who reportedly have modified findings to suggest Covid vaccines are pose a greater threat than they are.

Part of her “policy goals” for the incoming federal leadership included changing guidelines for recently developed shots and halting “non-essential” vaccines, she said after the election on a audio program. At the agency, Høeg has allegedly floated the idea of preventing young men from obtaining COVID-19 vaccines.

“She is an thorough true believer who commences with her beliefs and tailors the evidence to fit the evidence in a very misleading, untruthful way,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg became part of fellow dissenters, {like|